Novo Nordisk Shares Drop as Bank Downgrade Reflects Growth Concerns
The stock has tumbled 70% since its June 2024 peak, as the drugmaker has contended with intensifying competition from rival Eli Lilly as well as knockoff versions of its blockbuster Ozempic diabetes and Wegovy weight-loss jabs.
Best Buy Raises Outlook After Computing Growth Fuels 2Q Sales
The company now forecasts full-year adjusted earnings per share of $6.70 to $6.90, up from its prior guidance of $6.30 to $6.60.
Royal Bank Notches Record Earnings as Quarterly Results From Canada's Biggest Banks Beat Expectations
